[1]Airley RE, Mobasheri A, 2007. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy, 53(4):233-256.
[2]Bavelloni A, Ramazzotti G, Poli A, et al., 2017. MiRNA-210: a current overview. Anticancer Res, 37(12):6511-6521.
[3]https://doi.org/10.21873/anticanres.12107
[4]Brooks DL, Schwab LP, Krutilina R, et al., 2016. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer, 15:26.
[5]Heddleston JM, Li Z, Lathia JD, et al., 2010. Hypoxia inducible factors in cancer stem cells. Br J Cancer, 102(5): 789-795.
[6]Huang X, Le QT, Giaccia AJ, 2010. MiR-210—micromanager of the hypoxia pathway. Trends Mol Med, 16(5):230-237.
[7]Ivan M, Huang X, 2014. MiR-210: fine-tuning the hypoxic response. In: Koumenis C, Hammond E, Giaccia A (Eds.), Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging, and Therapeutic Targets. Springer, New York, p.205-227.
[8]Jemal A, Bray F, Center MM, et al., 2011. Global cancer statistics. CA Cancer J Clin, 61(2):69-90.
[9]Kai AKL, Chan LK, Lo RCL, et al., 2016. Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology, 64(2):473-487.
[10]Liu LL, Li DH, He YL, et al., 2017. miR-210 protects renal cell against hypoxia-induced apoptosis by targeting HIF-1 alpha. Mol Med, 23:258-271.
[11]Pugh CW, Ratcliffe PJ, 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med, 9(6):677-684.
[12]Semela D, Dufour JF, 2004. Angiogenesis and hepatocellular carcinoma. J Hepatol, 41(5):864-880.
[13]Siegel RL, Miller KD, Jemal A, 2018. Cancer statistics, 2018. CA Cancer J Clin, 68(1):7-30.
[14]Silakit R, Kitirat Y, Thongchot S, et al., 2018. Potential role of HIF-1-responsive microRNA210/HIF3 axis on gemcitabine resistance in cholangiocarcinoma cells. PLoS ONE, 13(6):e0199827.
[15]Wan LL, Zhang DQ, Zhang JN, et al., 2017. Anti-hepatocarcinoma activity of TT-1, an analog of melittin, combined with interferon-α via promoting the interaction of NKG2D and MICA. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(6):522-531.
[16]Wang LY, Zheng SS, 2018. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(7):497-504.
[17]Wang ZD, Qu FY, Chen YY, et al., 2017. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(1):27-36.
[18]Yang Y, Zhang J, Xia T, et al., 2016. MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. Oncol Rep, 36(5):2553-2562.
[19]Ying Q, Liang LH, Guo WJ, et al., 2011. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology, 54(6):2064-2075.
[20]List of electronic supplementary materials
[21]Table S1 Clinicopathological parameters of the patients
[22]Table S2 Univariate and multivariate analyses of survival in 424 patients with HCC according to clinicopathologic factors and miR-210 expression
<2161>
<1882>
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>